Company Overview
Pharma Research is a mid-sized South Korean biomedical company listed on the KOSDAQ exchange, specialising in hyaluronic acid-based medical devices and biomaterials. Its flagship products — sold under the Rejuran brand — belong to the polynucleotide (PDRN/PN) family of skin-regeneration treatments, which have earned the company a commanding position in South Korea's dermatology and plastic-surgery market. The company's founding chairman, Chung Sang-soo, remains the controlling shareholder, giving the firm the classic owner-operated structure common among South Korean mid-caps.
Despite consistently high profitability, Pharma Research had long been criticised by investors for returning too little cash to shareholders. When the South Korean government launched its "Korea Discount" remediation initiative — the so-called Value-Up Programme — in 2024, the company responded by expanding its dividend and formalising a shareholder-return policy. A cash dividend of 42.8 billion won announced in early 2026, accompanied by a declared payout ratio target of 25%, drew considerable market attention. Yet the withdrawal of a planned corporate spin-off has left governance reform and succession planning unresolved, and market opinion on the sincerity of the company's Value-Up commitment remains divided.
Business Fundamentals and Financial Performance
Core Products and Business Structure
Pharma Research's principal product is the Rejuran Healer, a skin-regeneration filler, alongside a broader range of polynucleotide-based medical devices. The company's proprietary technology extracts polynucleotide compounds from salmon DNA for application in skin repair and wound treatment. Growth has been driven primarily through domestic dermatology clinics and medical spas, though export revenues are reported to be rising steadily. The company's focus on high-margin aesthetic-medicine products has allowed it to sustain operating margins well above the industry average.
Financial Performance by Year
Year | Revenue | Operating Profit | Operating Margin | Net Profit
2021 | c.110bn won | c.35bn won | c.32% | c.28bn won
2022 | c.135bn won | c.45bn won | c.33% | c.36bn won
2023 | c.160bn won | c.54bn won | c.34% | c.43bn won
2024 | c.185bn won | c.62bn won | c.34% | c.50bn won
2025 (est.) | 200bn won+ | 65bn won+ | c.32–34% | TBC
Pharma Research has delivered consistent growth in both revenue and operating profit over recent years, driven by a favourable product mix weighted towards high-margin aesthetic treatments and expanding exports. Analysts caution, however, that intensifying competition and rising price pressure from rivals launching comparable products represent the principal threat to margin sustainability.
Value-Up Milestones
February 2026 — 42.8 Billion Won Cash Dividend: A Formal Commitment to Shareholder Returns
On 5th February 2026, Pharma Research announced via regulatory filing that its board had approved a cash dividend of 42.8 billion won — roughly three times the previous year's distribution. Management framed the decision as an expression of commitment to the government's Value-Up Programme and to enhancing long-term shareholder value. The principal beneficiary of the enlarged payout is Chairman Chung himself, whose stake entitles him to several tens of billions of won in dividend income. Some commentators were quick to question whether the measure represents genuine shareholder-friendliness or a mechanism for the controlling shareholder to extract cash from the company.
April 2026 — 25% Payout Ratio Target: Medium-Term Return Policy Formalised
In April 2026, Pharma Research publicly committed to a dividend payout ratio of 25%, establishing a formal medium-term framework for shareholder returns. Within the KOSDAQ biotech and pharmaceuticals sector, the announcement of a concrete payout target was broadly welcomed. Critics, however, noted that 25% remains well below the average for global healthcare companies, and questioned whether the company could sustain even this target should competitive pressures erode profitability.
April 2026 — Cited as a Leading KOSDAQ Value-Up Candidate
As debate around a "KOSDAQ 3000" Value-Up initiative gained momentum in April 2026, Pharma Research was cited as one of the more credible KOSDAQ candidates. Analysts pointed to its stable margins, the strength of the Rejuran brand, and its concrete shareholder-return commitments as factors in its favour. Governance concerns and succession uncertainty were nonetheless flagged as potential obstacles to a full Value-Up designation.
June 2026 — One Year Since the Spin-Off Withdrawal: Succession and Strategy Remain Unresolved
June 2026 marked one year since Pharma Research abandoned a planned spin-off that had been intended to separate its business divisions and clarify its succession structure. The plan was withdrawn in the face of shareholder opposition and market scepticism. A year on, no alternative roadmap has been disclosed, and analysts continue to flag governance uncertainty as a persistent drag on the company's valuation.
Challenges and Assessment
Key Challenges
For Pharma Research to substantiate its Value-Up credentials, three issues require resolution.
First, honouring the 25% payout ratio over the medium term. Delivering on this commitment requires sustained profitability in an increasingly competitive aesthetic-medicine market, where cost pressures are mounting.
Second, introducing additional shareholder-return mechanisms, particularly share buybacks and cancellations. As treasury-share cancellations become standard practice across the South Korean pharmaceutical and biotech sector, institutional investors are growing impatient with a dividend-only approach.
Third, resolving governance and succession transparently. Without a credible plan to restructure management and ownership after the spin-off withdrawal, the risks associated with founder-led control will continue to suppress the company's valuation multiple.
Overall Assessment
The direction of Pharma Research's Value-Up effort attracts cautious praise. Tripling the dividend and formalising a payout ratio target represents a genuine shift from a company long criticised for hoarding profits. The company's price-to-book ratio (PBR) is comparatively elevated within its peer group, reflecting market confidence in its growth prospects.
Nevertheless, the fact that the controlling shareholder is the primary beneficiary of any dividend increase is a structural limitation that cannot be easily dismissed. Until governance reform moves from intention to execution, the market is likely to apply a discount — reasonable, given that the risks are real rather than merely theoretical.
Controversies and Constraints
The Dividend Beneficiary Problem
The 42.8 billion won dividend and the 25% payout pledge appear, on their face, to be shareholder-friendly measures. In practice, however, the primary recipient is Chairman Chung, whose family holds a substantial proportion of the company's shares. Critics argue that large-scale dividend expansion in this context functions as much as a mechanism for transferring cash to the founding family as it does as a reward for all shareholders. Whether the policy is motivated principally by a desire to maximise shareholder value or by the controlling family's need for liquidity remains a live debate among investors.
The Abandoned Spin-Off and Governance Opacity
Pharma Research's attempt and subsequent failure to execute a spin-off exposed deep uncertainty about the company's long-term strategy and succession planning. Twelve months after the withdrawal, no credible alternative has been put forward. The concern in the market is that the company is adopting the outward form of Value-Up compliance whilst preserving an owner-centric management structure that is resistant to genuine reform.
The Absence of a Treasury-Share Policy
The industry trend towards treasury-share cancellations as a primary tool of capital return has not yet reached Pharma Research. A dividend-focused return policy delivers near-term cash to shareholders, but fails to address demand from institutional investors for the per-share value enhancement that buybacks and cancellations can provide.
Profitability Risk
A 25% payout commitment is only sustainable if earnings hold up. The aesthetic medical-device market in which Pharma Research operates is attracting rapid new entry from competitors, and the core Rejuran product faces potential patent expiry and price pressure. Should margins deteriorate, the company may find it difficult to maintain its payout target — a retreat that would be read by the market as a reversal of its Value-Up commitments.
Key Metrics Summary
Year | Cash Dividend | Payout Ratio | Buyback/Cancellation | Operating Profit (est.) | PBR (est.)
2022 | c.10bn won | c.8–10% | None | c.45bn won | c.5–7×
2023 | c.13bn won | c.9–10% | None | c.54bn won | c.6–8×
2024 | c.15bn won | c.10% | None | c.62bn won | c.6–9×
2025 | 42.8bn won | c.25% (target) | Not announced | 65bn won+ | TBC
2026 (target) | 25% maintained | 25% | Under review | Growth expected | —
Pharma Research has put concrete numbers behind its Value-Up commitment — a 42.8 billion won dividend and a 25% payout ratio target. Whether those numbers translate into a durable re-rating of the stock will depend on three things: the company's ability to sustain profitability in a toughening competitive environment; its willingness to extend shareholder returns beyond dividends to include share cancellations; and, above all, its readiness to address the governance and succession questions that a withdrawn spin-off left conspicuously unanswered.